

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

SAREPTA THERAPEUTICS, INC.,  
Petitioners,

v.

GENZYME CORPORATION,  
Patent Owner.

---

Case No. IPR2025-01195  
Patent No. 7,704,721

---

**PATENT OWNER'S MANDATORY NOTICES**

**MANDATORY NOTICES UNDER 37 C.F.R § 42.8**

Pursuant to 37 C.F.R. § 42.8, Patent Owner Genzyme Corporation states as follows:

**I. Real Party-in-Interest Under 37 CFR § 42.8(b)(1)**

Patent Owner Genzyme Corporation is a direct wholly-owned subsidiary of Aventis Inc. Genzyme Corporation and Aventis Inc. are indirect wholly-owned subsidiaries of Sanofi. Sanofi, the ultimate parent company of Genzyme Corporation, Genzyme Corporation, and Aventis, Inc. are the real parties-in-interest as Patent Owner.

**II. Related Matters Under 37 CFR § 42.8(b)(2)**

**A. U.S. District Court for District of Delaware Related Matters**

The following pending district court litigation may affect or be affected by this proceeding: *Genzyme Corp v. Sarepta Therapeutics, Inc.*, C.A. No. 24-cv-00882-RGA (D. Del.).

**B. Patent Trial and Appeal Board Co-Pending Matters**

Concurrently with the present Petition, Petitioner filed an *Inter Partes* Review (“IPR”) Petition challenging the patentability of certain claims of U.S. Patent No. 9,051,542 in IPR2025-001194. That IPR may affect indirectly or may be affected by the decision in this proceeding since both patents are related and involved in the Delaware litigation (*supra* § II.A).

### **C. Patent Trial and Appeal Board Past Matters**

Claims of the related U.S. Patent No. 9,051,542 were the subject of two IPR petitions, IPR2023-00608 and IPR2023-00609, brought by Novartis Gene Therapies, Inc. and Novartis Pharmaceutical Corporation. The Patent Trial and Appeal Board (PTAB) denied institution of both IPRs. *See Novartis Gene Therapies, Inc. v. Genzyme Corp.* IPR2023-00608, Paper 20 (PTAB Aug. 30, 2023); *Novartis Gene Therapies, Inc. v. Genzyme Corp.* IPR2023-00609, Paper 22 (PTAB Aug. 30, 2023).

### **III. Lead and Backup Counsel Under 37 C.F.R. § 42.8(b)(3)**

Patent Owner identifies the following designation of counsel:

| <b>Lead Counsel</b>                                                                                                                                                          | <b>Back-Up Counsel</b>                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amanda K. Antons Reg. No. 65,236<br>Dechert LLP<br>230 Northgate Street #209<br>Lake Forest, IL 60045<br>Tel: 312-646-5822<br>Fax: 212-698-3599<br>amanda.antons@dechert.com | Katherine A. Helm, <i>pro hac vice</i> to be applied for<br>Dechert LLP<br>Three Bryant Park<br>1095 Avenue of the Americas<br>New York, NY 10036-6797<br>Tel: 212-698-3500<br>Fax: 212-698-3599<br>khelm@dechert.com<br><br>Blaine M. Hackman, Reg. No. 67,479<br>Dechert LLP<br>Three Bryant Park<br>1095 Avenue of the Americas<br>New York, NY 10036-6797<br>Tel: 212-698-3500<br>Fax: 212-698-3599<br>blaine.hackman@dechert.com |

Pursuant to 37 C.F.R. § 42.10(b), Patent Owner is filing a power of attorney concurrently with this mandatory notice.

**IV. Service Information Under 37 C.F.R. § 42.8(b)(4)**

Patent Owner may be served at the above addresses for lead and back-up counsel. Pursuant to 37 C.F.R. § 42.6(e)(1), Patent Owner consents to electronic service by email.

Date: July 17, 2025

/Blaine M. Hackman/  
Blaine M. Hackman, Reg. No. 67,479  
Dechert LLP  
Three Bryant Park  
1095 Avenue of the Americas  
New York, NY 10036-6797  
Tel: 212-698-3500  
Fax: 212-698-3599  
blaine.hackman@dechert.com  
*Counsel for Patent Owner,*  
*Genzyme Corporation*

**CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. § 42.6(e), I certify that today in

*Sarepta Therapeutics, Inc., v. Genzyme Corporation*, IPR2025-01195

I caused to be served a copy of:

**PATENT OWNER'S MANDATORY NOTICES**

upon:

Sarepta Therapeutics, Inc. c/o:

robertwilson@quinnemanuel.com  
annetoker@quinnemanuel.com  
jimglass@quinnemanuel.com

via:

electronic service to the email addresses above.

Date: July 17, 2025

/Blaine M. Hackman/  
Blaine M. Hackman, Reg. No. 67,479  
Dechert LLP  
Three Bryant Park  
1095 Avenue of the Americas  
New York, NY 10036-6797  
Tel: 212-698-3500  
Fax: 212-698-3599  
blaine.hackman@dechert.com  
*Counsel for Patent Owner,*  
*Genzyme Corporation*